deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02042378

A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

A Phase 2, Open-Label Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

Sponsor: pharmaand GmbH

Conditions Pancreatic Cancer Pancreatic Ductal Adenocarcinoma
Interventions Rucaparib
Updated 12 times since 2017 Last updated: Jun 7, 2023 Started: Apr 30, 2014 Primary completion: Apr 30, 2016 Completion: May 31, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02042378, this PHASE2 trial focuses on Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma and remains completed. Sponsored by pharmaand GmbH, it has been updated 12 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshotCompleted~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshotCompleted~Apr 2019 – ~Feb 2020 · 10 months · monthly snapshotCompleted~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshotCompleted~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotCompleted~Apr 2022 – ~Jul 2023 · 15 months · monthly snapshotCompleted~Jul 2023 – ~Oct 2023 · 3 months · monthly snapshotCompleted~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jul 2023 — Oct 2023 [monthly]

    Completed PHASE2

  5. Apr 2022 — Jul 2023 [monthly]

    Completed PHASE2

▶ Show 7 earlier versions

  1. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE2

  2. Feb 2020 — Jan 2021 [monthly]

    Completed PHASE2

  3. Apr 2019 — Feb 2020 [monthly]

    Completed PHASE2

  4. Mar 2019 — Apr 2019 [monthly]

    Completed PHASE2

  5. Jun 2018 — Mar 2019 [monthly]

    Completed PHASE2

  6. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  7. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Apr 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • pharmaand GmbH
Data source: pharmaand GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations